U.S. flag

An official website of the United States government

NM_001625.4(AK2):c.455A>G (p.Tyr152Cys) AND AK2-related disorder

Germline classification:
Uncertain significance (1 submission)
Last evaluated:
Apr 14, 2024
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV004756932.1

Allele description [Variation Report for NM_001625.4(AK2):c.455A>G (p.Tyr152Cys)]

NM_001625.4(AK2):c.455A>G (p.Tyr152Cys)

Gene:
AK2:adenylate kinase 2 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
1p35.1
Genomic location:
Preferred name:
NM_001625.4(AK2):c.455A>G (p.Tyr152Cys)
HGVS:
  • NC_000001.11:g.33014565T>C
  • NG_016269.1:g.27327A>G
  • NM_001199199.3:c.431A>G
  • NM_001319139.3:c.311A>G
  • NM_001319140.2:c.311A>G
  • NM_001319141.3:c.455A>G
  • NM_001319142.3:c.329A>G
  • NM_001319143.2:c.360A>G
  • NM_001625.4:c.455A>GMANE SELECT
  • NM_013411.5:c.455A>G
  • NP_001186128.1:p.Tyr144Cys
  • NP_001306068.1:p.Tyr104Cys
  • NP_001306069.1:p.Tyr104Cys
  • NP_001306070.1:p.Tyr152Cys
  • NP_001306071.1:p.Tyr110Cys
  • NP_001306072.1:p.Leu120=
  • NP_001616.1:p.Tyr152Cys
  • NP_037543.1:p.Tyr152Cys
  • NP_037543.1:p.Tyr152Cys
  • LRG_133t1:c.455A>G
  • LRG_133:g.27327A>G
  • LRG_133p1:p.Tyr152Cys
  • NC_000001.10:g.33480166T>C
  • NM_001625.3:c.455A>G
  • NM_013411.3:c.455A>G
  • NR_134976.3:n.415A>G
Protein change:
Y104C
Molecular consequence:
  • NM_001199199.3:c.431A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001319139.3:c.311A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001319140.2:c.311A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001319141.3:c.455A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001319142.3:c.329A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001625.4:c.455A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_013411.5:c.455A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NR_134976.3:n.415A>G - non-coding transcript variant - [Sequence Ontology: SO:0001619]
  • NM_001319143.2:c.360A>G - synonymous variant - [Sequence Ontology: SO:0001819]

Condition(s)

Name:
AK2-related disorder
Synonyms:
AK2-related condition
Identifiers:

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV005358422PreventionGenetics, part of Exact Sciences
no assertion criteria provided
Uncertain significance
(Apr 14, 2024)
germlineclinical testing

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Details of each submission

From PreventionGenetics, part of Exact Sciences, SCV005358422.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided

Description

The AK2 c.455A>G variant is predicted to result in the amino acid substitution p.Tyr152Cys. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0065% of alleles in individuals of South Asian descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Oct 13, 2024